Hydrochlorothiazide vs Chlorthalidone: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.292 | 0.281 | 0.303 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.295 | 0.284 | 0.306 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0024 | -0.0177 | 0.0129 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.992 | 0.941 | 1.05 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.988 | 0.918 | 1.06 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with a serious adverse event on Hydrochlorothiazide than on Chlorthalidone | 417 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Hydrochlorothiazide | Hydrochlorothiazide daily dose of 50 mg or 25 mg for duration of study~Hydrochlorothiazide (HCTZ): Thiazide-type diuretic. Daily dose of 50 or 25 mg for duration of the study. | 1,977 | 6,767 | EG000 | ClinicalTrials.gov |
| Group 2 | Chlorthalidone | Chlorthalidone daily dose of 25 mg or 12.5 mg for duration of study~Chlorthalidone: Thiazide-type diuretic. Daily dose of 25 or 12.5 mg for duration of the study. | 1,990 | 6,756 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | Safety data collection was performed from study randomization until the participants deceased, withdrawn, or reached end of study (Up to 5.4 years for the first patient enrolled and an average of 2.4 years for all participants). | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Diuretic Comparison Project | ClinicalTrials.gov |
| NCT number | NCT02185417 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Hypertension | ClinicalTrials.gov |
| Interventions | Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD) | ClinicalTrials.gov |
| Lead sponsor | VA Office of Research and Development | ClinicalTrials.gov |
| Results first posted | 2024-05-22 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02185417?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.